Introduction: Among the various techniques established, lipid-based solid dispersion approach is one by which the bioavailability of BCS class II drug shall be significantly increased without affecting the permeability of drug. Aim __ampersandsignamp; Objective: The main aim of the current research work is to evaluate the potential of lipid-based solid dispersions of Azilsartan Medoxomil to enhance oral bioavailability of Azilsartan Medoxomil (BCS Class IV molecule). Methodology: ASD has been prepared using different hydrophilic lipid-based carriers such as gelucire 44/14 and gelucire 50/13 at the ratio of 1:1, 1:2 and 1:3. Pearlitol SD 200 was used as the hydrophilic carrier in all the formulations to convert the lipidbased solid dispersion to free-flowing powder. Solid dispersions were prepared by the solvent evaporation method. Prepared ASD__ampersandsignrsquo;s were evaluated for their micromeritics properties, saturation solubility, in vitro dissolution, and in vivo bioavailability in selected rats. Results: Among the formulations prepared, formulation (ASD6) containing gelucire 50/13 (1:3), Pearlitol SD 200 as the carrier has shown enhanced drug release (98.9 __ampersandsignplusmn; 1.9 release in 30 minutes) and solubility (65.57mg/mL) compared to other formulations. Hence, this formulation is evaluated for comparative in vivo bioavailability in rats along with pure drug and marketed formulation (Zilarbi). It was found that relative bioavailability of ASD6 was increased by 1.11 times compared to pure drug and increased by 1.04 times compared to marketed formulation. Conclusion: Hence, the study demonstrated that lipid-based solid dispersion technology can lead to improve the bioavailability of poorly soluble drugs like Azilsartan medoxomil significantly